je.st
news
Home
› Geron's Much Anticipated Imetelstat Phase 2 Study Grows To 50 Locations And Begins Enrollment
Geron's Much Anticipated Imetelstat Phase 2 Study Grows To 50 Locations And Begins Enrollment
2015-07-18 19:52:36| Biotech - Topix.net
Geron and partner Johnson & Johnson missed their self-imposed target date for the start of trial enrollment, yet Geron's stock hit its 52-week high post the deadline. I am speculating the delay may be driven by JNJ laying the groundwork for a possible Breakthrough Drug Therapy designation for Imetelstat.
Tags: study
locations
phase
begins
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||